Cosmetic & Skin Research

GHK-Cu 50mg Refill

£27.00

GHK-Cu 50mg Refill · 50mg nominal

the GHK-Cu copper-peptide complex in a refill presentation. The separately listed refill-cartridge product, not the complete pen. For in-vitro laboratory research only; not for human or veterinary use.

Request batch documentation

Description

GHK-Cu 50mg Refill is the Core Research catalogue item for 50mg nominal of the GHK-Cu copper-peptide complex in a refill presentation. It is supplied as the separately listed refill-cartridge product, not the complete pen for in-vitro laboratory research only; not for human or veterinary use. The material and model-level science below must be distinguished from product-specific analytical results and finished-format performance.

What you receive and what needs verifying

Field What this product listing establishes
Exact catalogue item GHK-Cu 50mg Refill
Labelled amount 50mg nominal; not an independently measured quantitative assay
Presentation the separately listed refill-cartridge product, not the complete pen
Research identity the GHK-Cu copper-peptide complex in a refill presentation
Supply boundary In-vitro laboratory research only; no personal or veterinary use
Current price and stock Shown by the live WooCommerce purchase panel; not fixed in this description

This is the refill-cartridge product, not the separately sold complete pen. Cartridge capacity, contents/vehicle, compatible hardware, sealed integrity, filled volume, accessories and dispensing tolerance should be established through documentation for this exact finished presentation. Do not transfer those details from a vial.

Before ordering, check the material identity, the form on the actual label and any information your assay needs from the applicable certificate. An unrelated paper, a general PubChem record or another catalogue format cannot establish a batch value for this particular item.

Which compound or format is the right laboratory item?

Different amount or format. GHK-Cu 50mg and 100mg are different labelled quantities. A vial and refill are different physical products. Neither item establishes the other’s supplied chemical form, measured copper content or lot test results.

Format or material Catalogue listing Evidence boundary
50mg vial GHK-Cu 50mg Separate catalogue record; verify its amount, components and lot evidence
50mg refill GHK-Cu 50mg Refill This item
100mg vial ghk-cu-100mg Separate catalogue record; verify its amount, components and lot evidence
100mg refill ghk-cu-100mg-refill Separate catalogue record; verify its amount, components and lot evidence
100mg pen ghk-cu-100mg-pen Separate catalogue record; verify its amount, components and lot evidence

The distinction is not cosmetic: a refill cartridge and an assembled pen answer different procurement questions. See vials versus pen formats and cartridge capacity and precision guide for the kinds of format data researchers should verify. A catalogue label is not a demonstrated compatibility or performance test.

Scientific research: mechanisms, measured results and limits

The following is a selected, model-specific evidence summary, not a systematic review, treatment recommendation or release test of this product. Read the study species, methods and measured endpoints beside each finding before transferring an interpretation to a different assay.

Copper coordination changes what must be specified

GHK is the tripeptide glycine–histidine–lysine, while GHK-Cu names a copper-associated complex. The underlying peptide sequence is useful reference information but does not, on its own, define copper stoichiometry, counter-ion composition, oxidation state, residual water or the mass basis used on a vial label. An analytical result for the free peptide should not be treated as automatically equivalent to a copper-complex assay. This distinction matters especially when comparing a 50mg vial, 50mg refill, and 100mg formats.

Epithelial-barrier and SIRT1–STAT3 experiments

In a 2025 investigation of a dextran-sulfate-sodium mouse colitis model and mouse epithelial/macrophage co-cultures, GHK-Cu was associated with changes in epithelial tight-junction proteins ZO-1 and occludin, inflammatory markers and SIRT1/p-STAT3 pathway measurements. A STAT3-silencing experiment removed the observed scratch-assay and junction-protein responses in that cell model. The authors also used molecular docking to nominate possible targets; docking is a hypothesis-generating technique, not confirmation that GHK-Cu directly binds SIRT1. These were non-human experimental systems. 1

Inflammatory pathways and the model-specific response

Park and colleagues investigated GHK-Cu in a lipopolysaccharide-induced acute lung-injury mouse model and reported changes in inflammatory readouts, including NF-κB and MAPK-associated signalling. A lung-injury model measures a particular inflammatory challenge; the presence of anti-inflammatory signals there does not establish the response of human skin, intestinal tissue, or any supplied laboratory batch. Results should be discussed as a pathway under investigation, not as a product-level health claim. 2

Matrix accumulation, fibrosis and oxidative stress

In bleomycin-related pulmonary-fibrosis research, Ma and colleagues examined oxidative-stress and inflammatory changes associated with GHK-Cu in a lung-injury model. Fibrotic tissue accumulation, collagen-related processes and tissue inflammation interact, but a measured reduction in fibrotic signals is not identical to clinically validated tissue rejuvenation. Experimental species, injury and dose context matter, and findings for a prepared test reagent do not assay the composition of this specific 50mg product. 3

Topical-formulation evidence is a separate evidence layer

Copper-tripeptide complexes have also been investigated in cosmetic and post-procedure topical formulations, including a study after CO2 laser resurfacing. The experimental vehicle, concentration and endpoint are integral to interpreting such studies. Results for a topical formulation cannot establish efficacy, safety or route suitability for a lyophilised research vial or cartridge; they also cannot verify the supplier’s copper content or batch purity. The value for researchers is the contrast between a compound-level mechanism and a formulated-product outcome. 4

How to interpret the evidence for this product

Research context Reported or relevant endpoint Interpretation limit
Mouse colon and epithelial co-culture ZO-1, occludin, p-STAT3 and scratch response Not human mucosal healing evidence
LPS mouse lung-injury model Inflammatory NF-κB/MAPK pathway markers Distinct injury model and tissue
Bleomycin-related lung fibrosis model Fibrotic and oxidative-stress markers Does not imply clinical cosmetic restoration
Topical clinical formulation research Formulation-specific appearance/recovery outcomes Not a test of dry vial or refill

Batch documentation before purchase

Core Research allows a pre-purchase batch-documentation enquiry. Use Batch Documentation or email info@core-research.net with the exact product name and presentation. An order or container lot number is not needed to ask the question before purchase; to match a supplied item after delivery, retain its lot identifier and order reference. The published delivery policy says a certificate is issued with a consignment where one exists for the supplied lot; that is not a promise of a current certificate for every item.

Ask whether documentation applies to the lot proposed for supply and identifies the tested chemical form, sample description, method, result, reporting basis, testing issuer and relevant dates. The difference between chromatographic peak-area purity, identity/mass and quantitative vial content matters.

For interpretation, use guide to reading a CoA, HPLC testing guide and mass-spectrometry guide. A theoretical molecular formula is not a batch-assay result, and a product label does not certify sterility.

For GHK-Cu 50mg, the material specification should distinguish copper-complex identity, copper and peptide mass bases, stoichiometry and counter-ion where relevant. A peptide HPLC purity percentage does not independently quantify total copper-complex content or the separate finished-cartridge performance.

Cartridge and finished-format verification

A compound-level HPLC/LC-MS report supports only the analyte/sample tested. It does not establish cartridge integrity, exact volume, device compatibility, dispensing accuracy or prepared-material stability. If any of these are essential to the intended experimental protocol, request documented values applicable to this exact refill and lot before ordering. pen verification guide covers the main verification questions.

Confirm in writing whether the product is supplied as a complete pen or a refill-only cartridge, and the included component list where not already clear from the listing. Do not infer an accessory or a specific solvent from an image or a sibling product.

Storage, receiving and laboratory quality control

A refill is not necessarily analytically or physically identical to a dry vial. Confirm whether the actual cartridge is filled with liquid or dry material before applying a liquid-stability or storage claim.

Follow the supplied label and product-specific documentation for storage conditions, temperature excursions and expiry. The time limits for dry peptide, a mixed solution, or a liquid-filled cartridge can differ. No generic fixed storage term, purity threshold or cold-chain guarantee is inserted here without applicable evidence. See peptide storage guidance and research-product receiving checklist for general laboratory-record practices.

At receipt, compare the product name, labelled amount and presentation with your order. Inspect the vial closure or cartridge/packaging, record the lot identifier and retain the accompanying paperwork. If damaged, delayed or different from the order, record photographs and contact Core Research before using the material. This records receipt conditions; it does not substitute for an identity assay.

Ordering questions

Does the labelled milligram amount state purity or a prepared concentration?

No. 50mg is the catalogue-labelled quantity for this item. It does not by itself establish analytical content, purity, final liquid concentration, sample mass basis or number of experiments. The applicable material documentation and your laboratory’s own method establish those details.

Where is the product dispatched from and what is the delivery policy?

Core Research states that it dispatches from Birmingham, United Kingdom, using plain external packaging. Delivery service, charge and arrival estimates depend on the destination and order; see Shipping & Delivery. Tracking is provided in dispatch communications where available. There is no universal next-day delivery or free-shipping promise on this page.

Can I obtain an applicable certificate before ordering?

You can request information before ordering through Batch Documentation. Specify GHK-Cu 50mg Refill, the refill presentation and any required test/method. Whether a particular current lot has a document, and what it actually reports, must be checked rather than assumed.

Can an institution request a quotation?

Yes. Institutional Procurement describes the written quotation and purchase-order-reference enquiry route. Include the institution, delivery details, exact product and quantity, and any lot or technical requirements. An enquiry does not itself reserve stock or guarantee credit terms.

Is this product suitable for human or veterinary use?

No. This listing is for in-vitro laboratory research only. Neither a positive model result nor a named medicinal compound establishes human-use suitability, and this page gives no preparation, dosing or administration instructions. See Research Use Only policy.

Order or enquire about GHK-Cu 50mg Refill

Use the native product purchase panel to select the listed quantity and the checkout options available for your order. For identity, format, lot-documentation or delivery questions, contact Core Research before purchase. Current price and stock remain controlled by WooCommerce, not hard-coded in this description.

Selected research references

[1] Mao S et al. (2025). Exploring GHK-Cu in a DSS-induced colitis mouse model and mouse-cell co-cultures. Frontiers in Pharmacology. PMID 40672369. DOI 10.3389/fphar.2025.1551843. Primary research record.

[2] Park J et al. (2016). GHK-Cu and LPS-induced acute lung injury in mice. Oncotarget. DOI 10.18632/oncotarget.11168. Primary research record.

[3] Ma et al. (2020). Protective effects of GHK-Cu in bleomycin-induced pulmonary fibrosis. Life Sciences. DOI 10.1016/j.lfs.2019.117139. Primary research record.

[4] Miller et al. (2006). Topical copper tripeptide complex after CO2 laser resurfacing: clinical cosmetic formulation context. Archives of Facial Plastic Surgery. DOI 10.1001/archfaci.8.4.252. Primary research record.

Additional information

Format

Refill cartridge

Strength

50mg